General Announcement::Information under Regulation 30 of SEBI (LODR) Regulations

Issuer & Securities

Issuer/ Manager
GLENMARK PHARMACEUTICALS LIMITED
Securities
GLENMARK PH US$200M4.5%210802 - XS1456577334 - 4N4B
GLENMARK PHARM US$170M2%220628 - XS1426780125 - 4G8B
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
28-Oct-2020 23:40:45
Status
New
Announcement Sub Title
Information under Regulation 30 of SEBI (LODR) Regulations
Announcement Reference
SG201028OTHRIMQZ
Submitted By (Co./ Ind. Name)
Glenmark Pharmaceuticals Ltd.
Designation
Company Secretary & Compliance Officer
Effective Date and Time of the event
28/10/2020 00:00:00
Description (Please provide a detailed description of the event in the box below)
Pursuant to Regulation 30 read with Schedule III Part A Para A (7) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we have to inform you that Mr. Milind Sarwate (DIN: 00109854) was appointed as Non-Executive Independent Director of the Company for a term of Five Years commencing from October 29, 2015 to October 28, 2020. Mr. Milind Sarwate, has conveyed that due to his pre-occupation, he would be unable to continue as Director on the Board of the Company post completion of his term as Non-Executive Independent Director with effect from close of business hours on October 28, 2020. Hence, Mr. Milind Sarwate ceases to be a Director of the Company from close of business hours on October 28, 2020.

Attachments

SGX_SE_Announcement_cessation.pdf
Total size =451K